Abstract
Objective: This study was designed to characterise the single and multiple dose pharmacokinetic profile of desloratadine, a new antihistamine, and its main metabolite, 3-hydroxy (3-OH) desloratadine, in healthy volunteers differing in sex and race.
Design: An open-label, parallel-group, single- and multiple-dose pharmacokinetic trial.
Intervention: A single 7.5mg oral tablet of desloratadine on day 1, followed by 7.5mg daily doses on days 4 to 17.
Participants: 48 healthy, nonsmoking volunteers (12 White men, 12 Black men, 12 White women, 12 Black women).
Main outcome measures: AUC24h and Cmax determined from serial blood samples of desloratadine and 3-OH desloratadine.
Results: There were no clinically relevant differences between men and women or Black participants and White participants for desloratadine and 3-OH desloratadine maximum plasma concentrations (Cmax) and area under the plasma concentration-time curve (AUC). Following multiple doses, the geometric mean Cmax was 5.17 μ,g/L in men, 5.68 μg/L in women, 5.87 μg/L in Black participants and 5.00 μg/L in White participants; the corresponding AUC from 0 to 24 hours (AUC24h) values were 77.9, 80.0, 90.6 and 68.8 μg/L · h. Corresponding 3-OH desloratadine geometric mean Cmax values were 1.93, 2.79, 2.20 and 2.45 μg/L, and the AUC24h values were 32.1, 47.5, 37.1 and 41.1 μg/L · h.
Conclusions: Oral administration of multiple doses of desloratadine 7.5mg, a dose 50% higher than the recommended 5mg clinical dose, was well tolerated by healthy adults differing in sex and race. Comparison of the Cmax and AUC values following 14 days of treatment with desloratadine indicates that no dosage adjustment is needed on the basis of sex or race.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Beierle I, Meibohm B, Derendorf H. Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 1999; 37: 529–47
Thurmann PA, Hompesch BC. Influence of gender on the pharmacokinetics and pharmacodynamics of drugs. Int J Clin Pharmacol Ther 1998; 36: 586–90
Gleiter CH, Gundert-Remy U. Gender differences in pharmacokinetics. Eur J Drug Metab Pharmacokinet 1996; 21: 123–8
Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50: 222–39
Johnson JA. Influence of race or ethnicity on pharmacokinetics of drugs. J Pharm Sci 1997; 86: 1328–33
Wood AJJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991; 20: 350–73
Meltzer EO, Premier BM, Nayak A. Efficacy and tolerability of once-daily 5mg desloratadine, an Hi-receptor antagonist, in patients with seasonal allergic rhinitis. Assessment during the spring and fall allergy seasons. Clin Drug Invest 2001; 21(1): 25–32
Gupta S, Banfield C, Affrime M, et al. Oral bioavailability of desloratadine is unaffected by food. Clin Pharmacokinet 2002; 41 Suppl. 1: 7–12
Affrime M, Gupta S, Banfield C, et al. A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clin Pharmacokinet 2002; 41 Suppl. 1: 13–19
Marino M, Glue P, Herron JM, et al. Lack of electrocardiographic effects of multiple high doses of desloratadine [abstract]. Allergy 2000; 55 Suppl. 63: 279
Acknowledgements
Supported by a research grant from Schering-Plough Research Institute, Kenilworth, New Jersey.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Affrime, M., Banfield, C., Gupta, S. et al. Effect of Race and Sex on Single and Multiple Dose Pharmacokinetics of Desloratadine. Clin Pharmacokinet 41 (Suppl 1), 21–28 (2002). https://doi.org/10.2165/00003088-200241001-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-200241001-00004